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ABST RACT
The metabolic syndrome represents a plethora of cardio-metabolic risk
factors including obesity, arterial hypertension, atherogenic
dyslipidemia, hyperglycemia, accompanied by pro-inflammatory and
pro-thrombotic state. The metabolic syndrome is one of the key risk
factors for certain types of cancer. Among these malignancies, breast
cancer and endometrial neoplasms require special attention.
Incriminated major causes for the development of breast and
endometrial cancer in metabolic syndrome patients are: the proinflammatory status and related cytokines, adipokine imbalances,
hyperestrogenism,
growth
factors,
disturbances
in
cancer
microenvironment, insulin resistance and hyperinsulinemia. The
metabolic syndrome consists of molecular dysregulations that create a
pro-oncogenic status. Our review aims at providing a better
understanding of the mechanisms underlying the link between the
metabolic syndrome and endometrial and breast cancer.

Introduction
Breast cancer (BC) ranks the first among solid cancers
in women, representing a major public health problem
globally [1], being a major cause of mortality in female
patients. With this in mind, the identification of modifiable
risk factors together with the implementation of primary
prevention methods should be considered a priority [1].
There are several studies that investigated the link between
the metabolic syndrome (MS) and BC with mixed results
regarding the implication of obesity, high blood pressure
and dyslipidemia. On the other hand, the association of the
aforementioned factors proved to increase the risk of
developing breast neoplasia [2]. Furthermore, endometrial
cancer (EC) is the most common form of gynecological
cancer in developed countries [3] and its association with
obesity, diabetes and hypertension (the endometrial cancer
triad) is irrefutable. Epidemiological studies have shown a
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2.45-fold higher risk of developing EC in overweight and
obese patients and 2.12-fold higher in diabetic patients. In
patients with obesity and hypertension, the risk of
developing EC is also increased [4].

Discussions
Metabolic syndrome
The metabolic syndrome represents a group of cardiometabolic risk factors including: obesity, arterial
hypertension, atherogenic dyslipidemia, hyperglycemia
together with pro-thrombotic and pro-inflammatory states
[5].
The World Health Organization’s (WHO) definition of
MS underwent several adjustments in time. According to
WHO, MS is characterized by the presence of: glucose
intolerance, impaired glucose tolerance, or diabetes
mellitus and/or insulin resistance together with two or more
of the parameters listed in Table 1 [5].
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Table 1. WHO definition of MS (5)
Parameters
1. High BP
2. High TG
3. Low HDL
4. Central Obesity
(Waist-to-Hip ratio)
or
BMI ≥30 kg/m2
5. Microalbuminuria

Description
≥140/90 mmHg
≥150 mg/dL
<35mg/dL in men and
<39mg/dL in women
>0.9 in men, >0.85 in
women

Urinary albumin
excretion rate
≥20mcg/min
Albumin-creatinine
ratio ≥30mcg/mg

BP- blood pressure, TG- triglycerides, HDL- high
density lipoprotein, BMI- body mass index
Endometrial cancer
Epidemiology
Endometrial cancer (EC) represents the most common
gynecological cancer in developed countries, with an
average incidence of 14.7/ 100,000 among women [3].
Risk factors
The risk factors associated with EC are body mass
index (BMI) ≥ 25, early menarche (before the age 12),
nulliparity, nulligravidity, the use of oral contraceptives,
infertility, positive family history of endometrial cancer,
low level of education. Additionally, there are also studies
that suggest an association between infertility treatments
and EC [6]. Regarding the involvement of smoking in the
development of EC, the results of the studies are
contradictory. While there are studies that have identified
an association between cigarette consumption and EC [7],
there are also studies that support the anti-estrogenic effect
of smoking [8,9] or studies that have not identified any
association between smoking and endometrial neoplasia
[6]. An increased body mass index (BMI) along with
increased waist circumference values are associated with
premenopausal uterine neoplasia [10]. High blood pressure
(HBP) appears to play a role in the development of EC, but
the underlying mechanism has not been elucidated to this
day [11,12]. Additionally, diabetes mellitus (DM) and
hyperinsulinemia have also been identified as risk factors
for EC [13,14].
The metabolic syndrome
As mentioned above, EC is a type of neoplasm
commonly associated with obesity, diabetes and
hypertension (the endometrial cancer triad) [4]. MS is
involved in the development of EC through the disruption
of blood glucose homeostasis, serum triglycerides levels,
168

Figure 1. Illustration of the metabolic syndrome
according to WHO (1)
insulinemia and insulin-like growth factor (IGF) system
[14,15].
Obesity
The increased risk for developing EC among women
suffering from obesity is based on the associated
hyperestrogenism,
hyper-insulinemia
and
insulin
resistance
(IR),
lipid
metabolism
disorders,
hyperglycemia, chronic inflammation [16].
Hyperestrogenism
A prolonged exposure of the endometrium to the
endogenous or exogenous estrogens, in the absence of the
antagonist effect of progesterone, represents the main
cause of EC. In menopausal women, the adipose tissue,
through the enzyme aromatase, which converts
androstenedione into estradiol, is the main source of
endogenous estrogen [17]. Thus, the serum estradiol
resulting from this process interacts with endometrial
estrogen receptors [17].
Hyperestrogenemia may also be the result of
hyperinsulinemia, common in obese patients [18].
Elevated insulin levels lead to a decrease in sex hormone
binding protein (SHBP) synthesis and an increased
bioavailability of insulin-like growth factor 1 (IGF-1) [18].
Insulin resistance, in the context of elevated serum levels
of adipokines (leptin and visfatin) and pro-inflammatory
cytokines (TNF-α, IL-1β, IL-6, MCP-1), underlies
hyperinsulinemia, characterized by low serum IGF-1
binding protein resulting in elevated levels of IGF-1 [19].
High levels of insulin and IGF-1 stimulate endometrial
cancer cell proliferation by binding to insulin receptors
(IR) and IGF-1 receptors (IGF-1R) [20]. There are studies
that have demonstrated the synergic effect of insulin and
estrogen in the stimulation of endometrial tumor cell
proliferation [21].
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Chronic inflammation
Obesity is characterized by a chronic pro-inflammatory
status characterized by the infiltration of the adipose tissue
with macrophages and an increased expression of
inflammatory cytokines, which represent an important
factor involved in IR [19]. Studies on human and animal
subjects with obesity and IR revealed elevated plasma
levels of C-reactive protein (CRP) and interleukin-6 (IL-6)
[22].
Growth factors
The activity of (VEGF-mTOR)– (the vascular
endothelial growth factor - mammalian target of
rapamycin) factor is highly increased in obese women with
endometrial neoplasm. There are studies proposing VEGFmTOR derived from adipocytes as a possible therapeutic
target in obese women diagnosed with EC [23].
Cancer microenvironment
The adipose tissue can disturb the tumor
microenvironment by inducing disturbances in the
extracellular matrix, thus dysregulating the homeostasis of

the surrounding tissues and creating a favorable status for
the development of cancer. In addition to the indirect
effects, adipose tissue also acts directly on neoplastic cells
through a paracrine mechanism [24]. In addition, there are
studies that have reported the possibility of a fusion
capacity between endometrial malignant cells and adiposederived stem cells (ASC), with the subsequent expression
of a fibroblast-like phenotype [25]. All the above are
associated with a phenomenon of downregulation of Ecadherin expression and upregulation of Vimentin
expression [25].
Pro-inflammatory cytokines and adipokines
The roles of cytokines in the regulation of metabolism and
inter-organ signaling outline the relationship with
pathophysiology in metabolic disease. Over nutrition along
with low physical activity (a sedentary lifestyle) has led to an
increase in metabolic diseases. Several organs and tissues
(e.g., adipocytes, hepatocytes, muscles, skeleton cells) secrete
specific cytokines for inter-organ communication, and the
secretion of these cytokines is modified during nutritional
stress and physical activity [26,27].

Table I. A summary of the main cytokines and their effects on glucose and lipid metabolism (decreased glucose
tolerance, decreased insulin signaling, increased insulin resistance, decreased beta cell function, increased
triglycerides synthesis)
Inflammatory
cytokines

Adipokines

Hepatokines

Myokines

Osteokines

TNF-α ↑

Leptin ↑

Fetuin A, B ↑

IL-13 ↓

Osteopontin ↑

IL-1β ↑

Adiponectin ↓

Hepassocin ↑

IL-15 ↓

Osteocalcin ↓

IL-6 ↑

Resisitin ↑

FGF21 ↑

BDNF ↓

FGF23 ↑

MCP-1 ↑

Asprosin ↑

Selenoprotein P ↑

Irisin ↓

Sclerostin ↑

TNF-α: tumor necrosis factor; IL: interleukins; MCP-1: Monocyte Chemotactic Protein 1; FGF21: fibroblast growth
factor 21; FGF23: fibroblast growth factor 23; BDNF: Brain-Derived Neurotrophic Factor.
Adiponectin, visfatin and leptin are adipokines
involved in the development and progression of EC [16].
Obesity,
hypertension,
insulin
resistance
and
hyperinsulinemia are associated with low serum
adiponectin [28], which is further correlated with the risk
of developing EC in postmenopausal women who have not
received hormone replacement therapy (HRT) [28].
Adiponectin is a cytokine secreted by adipocytes and with
low circulating levels in patients diagnosed with EC [29].
Adiponectin exerts its effects through its receptors: the
adiponectin receptor-1 (AdipoR1) and the adiponectin
receptor-2 (AdipoR2) [30]. An increase in AdipoR1
expression compared to the expression of AdipoR2 was
identified in EC. AdipoR1 plays a role in the inhibition of
neoplastic cell proliferation, intercellular adhesion and the
invasiveness of EC [31] and increases cancer cell insulin
sensitivity [32]. Moreover, adiponectin also has an effect

on the tumor microenvironment [33]. Thus, the low serum
level of adiponectin, found among obese people, is closely
related to the risk of developing endometrial neoplasm
[34].
Visfatin (Visf) is an insulin-like adipokine. Elevated
serum levels of Visf were found in patients diagnosed with
EC [35], and its serum level increases with the patients’
BMI [36,37]. Given that the ratio of Visf:Adipo is elevated
in EC, studies have shown that a high serum level of Visf
represents an independent risk factor for EC [38].
Moreover, the Visf level is associated with the risk of
myometrial invasion, lymph node metastases and a poor
prognosis for patients diagnosed with EC [36,37].
Leptin (Lept) represents another adipokine which is
involved not only in the development of endometrial, but
also in breast and colon neoplasm pathogenesis. By
interacting with the leptin receptor (ObR), it plays an
169
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important role in regulating food intake, energy
consumption and cell growth [39,40]. Zhou et al.
demonstrated that the serum level of Lept, together with
the expression ObR, is strongly correlated with the degree
of EC differentiation.
Thus, ObRs are intensely expressed in poorly
differentiated tumors [41]. Additionally, the serum level of
Lept is an independent risk factor for EC [42]. The cells’
malignant transformation, their proliferation and invasion
capacities are based on the Lept over-activation of the
PI3K / Akt [42], JNK, STAT3, ERK1 / 2 signaling
pathways [43,44].
Inflammation plays a crucial role in tumorigenesis. In
patients suffering from obesity, the adipose tissue
represents the site of a marked inflammatory process
responsible for systemic metabolic alterations and tumor
microenvironment disturbances [16].
Interleukin-6 (IL-6), tumor necrosis factor alpha (TNFα) and plasminogen activator inhibitor-1 (PAI-1) are proinflammatory cytokines involved in tumorigenesis in obese
people [16].
IL-6 is an inflammatory cytokine, associated with an
increased risk of mortality in overweight/obese people
[45]. Elevated IL-6 levels represent a predictive factor for
poor prognosis in cancer patients [46]. Moreover,
estrogen hormones promote cellular IL-6 expression in
EC [47].
In turn, IL-6 supports the synthesis of aromatase, thus
accelerating the synthesis of estrogen and creating a
positive feedback mechanism [48]. The IL-6 / JAK /
STAT3 signaling pathway is also involved in the
development of neoplasms. IL-6 causes the hyperactivation of the aforementioned pathway, which is
associated with an unfavorable prognosis in cancer
patients [49]. Additionally, there are studies that
confirmed that by blocking the IL-6 inflammatory signal,
the spread of neoplastic cells to the liver may be inhibited
[49,50].
TNF-α is an endogenous tumor-promoting factor
secreted by macrophages and adipocytes, involved in the
proliferation, invasion and metastasis of tumor cells [51].
Adipocytes can stimulate endometrial cell proliferation
through a paracrine mechanism that appears to be mediated
by TNF-α [51]. By activating the NF-Κb signaling
pathway, TNF-α inhibits the apoptosis of the neoplastic
cells [16].
PAI-1 is a protease inhibitor produced in endothelial,
stromal and adipocyte cells [16]. It plays an important role
in the invasion and metastasis of tumors associated with
obesity [52]. The increased expression of PAI-1 in
endometrial neoplastic cells is associated with a poor
prognosis, and an increased risk of disease recurrence [53].
170

Diabetes mellitus
Diabetes mellitus (DM) is a well-known risk factor for
EC [54], and it is associated with increased mortality
among EC patients [55].
Hyperglycemia
Hyperglycemia acts directly on the signaling pathways
involved in the rapid proliferation of tumor cells [56]. In
addition to a rapid source of energy, glycolysis is also
responsible for the production of a plethora of metabolic
intermediates, used for the synthesis of macromolecules,
such as: nucleic acids, fatty acids and proteins, essential in
supporting the rapid growth of tumors [16].
Hyperglycemia supports the proliferation and invasion
of endometrial neoplastic cells through the promotion of
VEGF expression, its receptor (VEGFR), and the
epithelial-mesenchymal transition (EMT) process by
regulating Erα/GLUT4 (glucose transporter) expression
[57]. In addition, hyperglycemia supports the proliferation
of endometrial neoplastic cells by activating STAT3
expression [58].
An enzyme involved in glycolysis is isoenzyme M2 of
pyruvate kinase (PKM2), which not only plays an
important role in tumorigenesis, but also in the prognosis
of cancer patients [59].
Lactic acid (LA) is a key metabolite in the neoplastic
cell glycolysis. It supports the transformation of normal
cells into tumor cells, it has an immunosuppressive effect
and promotes angiogenesis [60]. Furthermore, LA
promotes the transition of M1 anti-tumor macrophages into
M2 macrophages, which represent the predominant
population of macrophages associated with EC [61]. The
uptake of pyruvate and LA by cells is achieved through
monocarboxylate transporter 1 (MCT1), which is an
independent marker for EC prognosis [62].
Hyperinsulinemia and Insulin resistance
Insulin resistance and hyperinsulinemia play an
important role in the development of EC. Moreover,
hyperinsulinemia is an independent risk factor for EC [63].
Elevated serum insulin levels together with IGF-1/2
accelerate the conversion of androstenedione into estrogen
via aromatase, and also inhibit SHBG synthesis in patients
with diabetes [16]. Prolonged exposure to estrogen without
the antagonistic effect of progesterone is a well-known risk
factor for endometrial dysplasia and malignant
transformation [64]. Additionally, IR / IGF-1R are
prognostic factors associated with lymph node invasion
[65].
Given the involvement of hyperinsulinemia in the
development of EC, there are studies that have investigated
the potential anti-neoplastic effect of metformin. There are
data in the literature suggesting that the combination
between metformin with progesterone therapy may have a
beneficial effect in patients with an unsatisfactory response
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to progesterone therapy [66]. Conventional doses of
metformin proved to be effective for hyperglycemia and
elevated IGF-1 level management in patients with EC [67].
A meta-analysis conducted in 2018 failed to prove the
protective effect of metformin against the development of
EC, but showed its beneficial effect in terms of survival
and risk of recurrence [68]. However, there are also studies
that do not support the beneficial effects of metformin in
EC management [69].
Dyslipidemia
The association between hyperglycemia, hyperlipemia
and HBP doubles the risk of developing EC [70]. A positive
correlation has been identified between the EC patients’
BMI and the serum level of palmitic, oleic and stearic acid
[71]. An elevated plasma level of eicosapentaenoic acid is
also associated with EC recurrence [72]. Noteworthy is that
there are studies that have proven the antitumor effect of
fatostatin, which has inhibitory effects on the proliferation of
neoplastic endometrial cells and also induces the apoptosis
of neoplastic cells [73].

Weight loss
Bariatric surgery or weight loss may reduce the risk of
developing endometrial hyperplasia or EC [74]. Weight
loss in patients with EC decreased C-peptide, insulin, CRP,
leptin, IL-1Rα and IL-6 levels and increased SHBG, IGFBP1 and adiponectin levels [75]. Therefore, bariatric
surgery can reduce the risk of developing EC by reducing
obesity-associated inflammation [16].
Breast cancer
As mentioned above, breast cancer (BC) ranks as the
first type of cancer among women, representing a major
public health problem globally. There are several studies
that have investigated the link between MS and BC.
Numerous epidemiological studies analyzed the causal
relationship between the metabolic syndrome or its
individual components and BC (1).
Risk factors
The risk factors for breast cancer are presented in the
Table 2.

Table 2. Risk factors for breast cancer [76]
Risk factors

Examples

mechanism/ higher risk

Genetic factors

BRCA 1/2

The mutations of those genes are associated with an
increased risk of BC

HER 2

The overexpression of the HER 2 oncogene is present in
20% of BC

EGFR

EGFR overexpression is present in more than 30% of
inflammatory BC

c-Myc

c-Myc overexpression is common in invasive BC

RAS

The H-RAS overexpression is identified in BC and it is
associated with a reserved prognosis

Age

BC incidence increases with age

Sex

Female sex

Demographic factors

Positive family history for CS in first-degree relatives is
an increased risk factor for breast cancer

Family history
Reproductive history

Early menarche

Represent risk factors for BC

Late menopause
Age of the first
pregnancy
Hormones

Estrogens

Lifestyle

High fat diet (especially
saturated fats)

Both endogenous and exogenous estrogens are risk
factors for CS

Represent risk factors for BC

Alcohol consumption
Smoking
BC- breast cancer
171
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The metabolic syndrome and breast cancer
Numerous epidemiological studies analyzed the
causal relationship between the metabolic syndrome or
its individual components and BC. Therefore, several
studies have revealed a correlation between diabetes and
breast cancer, while there are inconclusive results
regarding the role of obesity, high blood pressure and
dyslipidemia. Although there is a rather weak
association between the individual components of the
metabolic syndrome and the development of breast
cancer, their combination could increase the risk of
developing breast neoplasia [2].
The relationship between MS and breast cancer was
investigated in a large population study that included
94,000 women, which was conducted over a period of 14
years; during this time, 5.7% of the women developed
breast cancer [77]. The risk of breast cancer increased with
the number of MS components, being 45% higher in
women who had 4 MS components than in those without
MS [77].
Mechanisms
The metabolic syndrome consists in certain endocrine,
metabolic and physiological immunological disturbances
that can disrupt the molecular pathways involved in the
pathogenesis of BC.
Aromatase
An increased aromatase activity along with an
increased level of inflammation have been identified in
the adipose breast tissue of overweight and obese women
[78].
Aromatase activity is responsible for
hyperestrogenemia in obese patients (79). Low plasma
SHBG levels are associated with IR and other
components of the metabolic syndrome [79]. It is well
known that estrogen plays an important role in hormonedependent breast cancer.
Adipokines
The disturbances in the adipokines secretion are also
involved in the pathogenesis of BC. Increased levels of
leptin and decreased levels of adiponectin were found in
obese patients. Leptin stimulates breast cell proliferation
while adiponectin has a protective effect by inhibiting
uncontrolled cell growth [2].
Insulin resistance and diabetes mellitus
IR has an important pathogenetic role in BC.
Hyperinsulinism represents a compensatory mechanism
for IR, with the consequent binding of insulin to specific
receptors in breast epithelial cells, leading to the activation
of the IGF 1 signaling pathway, a pathway known to be
involved in carcinogenesis. In addition, hyperinsulinism
may contribute to the development of breast cancer by
stimulating hepatic IGF-1 production [80].
172

Agnoli et al. demonstrated the link between MS and BC
in a multicenter study and identified the presence of altered
fasting blood glucose in patients with MS and BC [81].
Chronic inflammation
Another important feature of MS with implications in
tumorigenesis is the chronic inflammation present in these
patients, expressed through the secretion of cytokines such
as interleukin-6 and tumor necrosis factor alpha that
support EC progression [82].
The metabolic syndrome and various types of breast
cancer
Four subtypes of BC have been described, each one of
them being different in terms of prognosis, treatment
options, the presence of estrogen and progesterone
hormone receptors, HER2 expression and ki-67
proliferation index [77]. There are several studies in the
literature that took into consideration the aforementioned
subtypes of BC and showed that the association between
breast cancer and the metabolic syndrome is significant
only for ER positive BCs [77]. Given the pathogenetic
mechanisms described above, in particular the role of
estrogen, the risk is expected to be higher for hormonedependent tumors.
Another study investigated the link between MS and
triple negative BC [83]. The authors reported a higher
prevalence of MS in triple negative cancer patients (58%
compared to 37% for other cancers), but without a wellestablished causal relationship [83].
The metabolic syndrome and the therapeutic response
in breast cancer
The potential implications of MS in the treatment
outcomes of BC patients were also investigated.
Noteworthy is the association of MS with a high
cardiovascular risk and the cardiotoxicity of certain
oncological treatments for breast cancer (especially
anthracycline-based chemotherapy and anti-HER2
monoclonal antibodies). A higher risk of cardiotoxicity
was demonstrated in overweight and obese patients [84].
A low adiponectin production in obese people might
represent the explanation for the adverse cardiovascular
effects of oncological therapy in obese patients. Animal
studies have shown an exacerbation of myocardial
dysfunction after the injection of doxorubicin in mice
with adiponectin depletion and an improvement in
cardiac
dysfunction
induced
by
doxorubicin
administration after the exogenous injection of
adiponectin [85].
Preliminary data
The link between MS and cancer is clearly
established. There are several meta-analyses in the
scientific literature that showed a significant increase in
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the incidence of BC in women suffering from MS. At the
same time, the authors noted a higher risk in
postmenopausal women, thus suggesting the different
pathophysiology behind the genesis of pre- and postmenopausal BC [2,86].
Recent data, from a recent meta-analysis of 17 cohort
observational studies, confirm a strong association
between the metabolic syndrome and breast cancer (RR
= 1.15, CI: 1.05-1.26, p = 0.003) [82]. An increased risk
was also observed among Caucasian women [82].
The prognostic role of MS in patients with breast
cancer was also studied in a recent meta-analysis [87]
that included 9 cohort studies with over 17,000 patients
diagnosed with BC. The aforementioned study showed
that the presence of MS was associated with an
increased risk of breast cancer recurrence ([RR] = 1.52,
95%, p = 0.02) and overall mortality [87]. The
conclusion of this meta-analysis was that MS is an
independent predictive factor for negative prognosis in
women with BC [87]. The above findings are consistent
with the results of another study which showed that the
risk of developing distant metastases is more than
double in women with BC and MS than in those with
breast cancer without MS [88].
All the above demonstrate that the association
between cancer and MS represents an intensely debated
subject with a complicated pathophysiology based on
multiple, intricate mechanisms. Our paper attempts to
shed some light over the underlying mechanisms that link
MS to BC and EC.
As mentioned above, the main mechanism underlying
hyperestrogenism in overweight and obese patients is the
conversion of androgens into estrogens through the action
of aromatase present in the adipose tissue, thus,
increasing the circulating estradiol [79], all together with
the reduced levels of plasma concentration of sex
hormone transport protein (SHBG) [78]. The activation
of the signaling pathway is accomplished by binding
estrogens to ERα receptors, with their consequent
dimerization, translocation in the nucleus, followed by
gene transcription and protein synthesis with a role in cell
proliferation [89].
The disruption of adipokine levels cancels the
protective effect of adiponectin against uncontrolled cell
growth, while the increased levels of leptin stimulate breast
cancer cell proliferation [2].
Insulin resistance and the consequent hyperinsulinism
lead to the IGF-1 signaling pathway activation.
Furthermore, in the context of hyperinsulinemia, the liver
IGF-1 production is stimulated [81], this being another
important mechanism involved in BC pathogenesis.
In addition to the aforementioned pathways involved in
BC pathophysiology, the chronic inflammatory state that
defines MS and is characterized by increased levels of pro-

inflammatory cytokines (IL-6 and TNF-alpha) also plays a
role in breast tumorigenesis [82]. The mechanisms that
mediate the crosstalk between MS and BC are presented
in Figure 2.

Figure 2. The major mechanisms linking MS to BC
pathogenesis. The active adipose tissue disrupts the
adipokine homeostasis by producing high levels of
leptin, while the adiponectin levels are decreased, thus
creating a pro-tumorigenic state. Additionally, the
chronic pro-inflammatory status, characterized by the
secretion of inflammatory cytokines (IL-6, TNF-alpha),
regulates several processes in tumorigenesis. The
increased adipose tissue aromatase activity is
responsible for the high circulating estrogens that
mediate epithelial cell proliferation by interacting with
the estrogen receptors. Additionally, hyperinsulinism
stimulates the liver production of IGF-1, its high
circulating levels increasing the risk of developing
breast cancer.
Obesity, diabetes and hypertension represent the
metabolic triad of EC. Insulin resistance, leptin, lactate
along with low serum adiponectin and obesity-associated
chronic inflammation are important factors involved in EC
occurrence [4].
As mentioned above, increased estrogen levels
represent a risk factor for EC. In overweight and obese
patients, increased adipose tissue aromatase activity is
responsible
for
peripheral
estrogen
synthesis.
Hyperestrogenemia may be the result of hyperinsulinemia
by reducing the synthesis of SHBP [18]. As in the case of
BC, the chronic inflammation characterized by high levels
of pro-inflammatory cytokines (IL-6, TNF-alpha, PAI-1)
supports tumorigenesis in obese female patients [16,22].
The adipokines homeostasis is deregulated in MS patients,
thus, the dysregulation of Visf:Adipo balance, with high
Visf levels, is associated with EC aggressiveness and a
poor prognosis [36,37].
Hyperglycemia not only disrupts the signaling
pathways responsible for the rapid cell proliferation in
cancer (STAT3, PKM2) but it also favors the EMT via
Erα/GLUT4 [57-59]. Figure 3 exemplifies the underlying
mechanisms that link MS to EC.
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diabetes, dyslipidemia and visceral obesity. Most of the
molecular disturbances induced by MS are involved in the
development, progression and prognosis of BC and EC.
More importantly, although the studies of the association
between the metabolic syndrome and cancer have shown
contributions of genetic, biological factors (age, gender,
ethnicity), MS represents an association of modifiable
factors and this not only highlights the importance of
improving lifestyle, balanced diet and regular physical
activity in cancer prevention, but also the importance of
combining these measures in the management of patients
diagnosed with this disease, thus, in preventing morbidity
and mortality in tumors associated with the metabolic
syndrome.
Figure 3. The underlying mechanisms that link MS
to EC
In overweight/obese patients, the active adipose tissue
produces high levels of leptin and visfatin, while the
adiponectin levels are decreased creating a protumorigenic state. Leptin hyperactivates the PI3K/Akt,
JNK, STAT3, ERK1/2 signaling pathways, thus
mediating the malignant transformation of endometrial
cells and their proliferation. Additionally, there is a
chronic pro-inflammatory status, characterized by the
secretion of inflammatory cytokines: IL-6, TNF-alpha
and PAI-1. The hyperactivation of IL-6/JAK/STAT3
signaling pathway regulates tumorigenesis, being
associated with poor prognosis. The increased adipose
tissue aromatase activity is responsible for the high
circulating estrogens that mediate epithelial cell
proliferation by interacting with estrogen receptors. The
aromatase activity is accelerated by IGF-1/2, which also
inhibits the synthesis of SHBP in patients with diabetes
mellitus. The invasive phenotype of endometrial cancer
cells is supported through the activation of VEGFmTOR pathway. Additionally, hyperinsulinism
stimulates the liver production of IGF-1, its high
circulating levels increasing the risk of developing
breast cancer. Hyperglycemia is responsible for cancer
cell proliferation through the overexpression of
VEGF/VEGFR and STAT3. Regarding the tumor
microenvironment, the E-cadherin downregulation
together with vimentin upregulation are associated with
the epithelial–mesenchymal transition.

Highlights
✓ A comprehensive summary of the mechanisms
underlying the link between the metabolic syndrome
and endometrial and breast cancer
✓ The implication of inflammatory changes associated
with the metabolic syndrome in oncogenesis

Conclusions
In conclusion, the metabolic syndrome is a complex
condition
characterized
by
insulin
resistance,
hyperinsulinemia, impaired glucose tolerance, type II
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